These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation. Metzner B; Pott C; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH Ann Oncol; 2013 Jun; 24(6):1609-15. PubMed ID: 23393125 [TBL] [Abstract][Full Text] [Related]
3. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447 [TBL] [Abstract][Full Text] [Related]
4. Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Metzner B; Müller TH; Casper J; Kimmich C; Köhne CH; Petershofen E; Renzelmann A; Thole R; Voss A; Dreyling M; Hoster E; Klapper W; Pott C Eur J Haematol; 2023 Aug; 111(2):220-228. PubMed ID: 37094812 [TBL] [Abstract][Full Text] [Related]
5. Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease. Metzner B; Welzel J; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voss A; Willborn K; Köhne CH Strahlenther Onkol; 2022 Jan; 198(1):39-46. PubMed ID: 34735577 [TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. Kothari J; Peggs KS; Bird A; Thomson KJ; Morris E; Virchis AE; Lambert J; Goldstone AH; Linch DC; Ardeshna KM Br J Haematol; 2014 May; 165(3):334-40. PubMed ID: 24438080 [TBL] [Abstract][Full Text] [Related]
7. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971 [TBL] [Abstract][Full Text] [Related]
8. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097 [TBL] [Abstract][Full Text] [Related]
9. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600 [TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. Bento L; Boumendil A; Finel H; Le Gouill S; Amorim S; Monjanel H; Bouabdallah R; Bay JO; Nicolas-Virelizier E; McQuaker G; Rossi G; Johnson R; Huynh A; Ceballos P; Rambaldi A; Bachy E; Malladi R; Orchard K; Pohlreich D; Tilly H; Bonifazi F; Poiré X; Guilhot F; Haenel A; Crawley C; Metzner B; Gribben J; Russell NH; Damaj G; Thomson K; Dreger P; Montoto S Bone Marrow Transplant; 2017 Aug; 52(8):1120-1125. PubMed ID: 28530668 [TBL] [Abstract][Full Text] [Related]
11. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. Alig S; Jurinovic V; Shahrokh Esfahani M; Haebe S; Passerini V; Hellmuth JC; Gaitzsch E; Keay W; Tahiri N; Zoellner A; Rosenwald A; Klapper W; Stein H; Feller A; Ott G; Staiger AM; Horn H; Hansmann ML; Pott C; Unterhalt M; Schmidt C; Dreyling M; Alizadeh AA; Hiddemann W; Hoster E; Weigert O Blood Adv; 2020 Sep; 4(18):4451-4462. PubMed ID: 32941649 [TBL] [Abstract][Full Text] [Related]
12. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Gkotzamanidou M; Papadimitriou CA Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060 [TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963 [TBL] [Abstract][Full Text] [Related]
14. [Follicular lymphoma: first - line selection criteria of treatment]. Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757 [TBL] [Abstract][Full Text] [Related]